Rapamycin-Resistant Polyclonal Th1/Tc1 Cell Therapy (RAPA-201) Safely Induces Disease Remissions in Relapsed, Refractory Multiple Myeloma

0
11
The clinical trial evaluated RAPA-201 therapy in combination with fludarabine-sparing low-dose host conditioning for the treatment of patients with relapsed, refractory multiple myeloma.
[Journal For Immunotherapy of Cancer]
Full Article